Literature DB >> 6895752

Studies of the capacity of factor Xa to protect factor Va from inactivation by activated protein C.

M E Nesheim, W M Canfield, W Kisiel, K G Mann.   

Abstract

Blood coagulation Factor Xa and activated protein C are both serine proteases derived from circulating, vitamin K-dependent precursors. They express, respectively, procoagulant and anticoagulant properties through Ca2+ and phospholipid-dependent interactions with coagulation Factor Va. The present studies were undertaken to determine whether Factor Xa and activated protein C interact independently or competitively with Factor Va. The interactions were assessed by examining the activated protein C-catalyzed inactivation of Factor Va in the absence and presence of Factor Xa at various concentrations. The results indicated that the two proteins compete for Factor Va and that Factor Xa protects Factor Va from inactivation by activated protein C. The ability of Factor Xa to protect Factor Va was observed either in the absence of a Factor Xa substrate or under conditions in which the complex of Factor Va and Factor Xa was engaged in the conversion of substrate (prethrombin 1) to thrombin.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6895752

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  20 in total

Review 1.  Anticoagulant proteins from snake venoms: structure, function and mechanism.

Authors:  R Manjunatha Kini
Journal:  Biochem J       Date:  2006-08-01       Impact factor: 3.857

Review 2.  The interaction between complement component C4b-binding protein and the vitamin K-dependent protein S forms a link between blood coagulation and the complement system.

Authors:  M Hessing
Journal:  Biochem J       Date:  1991-08-01       Impact factor: 3.857

3.  Anticoagulant synergism of heparin and activated protein C in vitro. Role of a novel anticoagulant mechanism of heparin, enhancement of inactivation of factor V by activated protein C.

Authors:  J Petäjä; J A Fernández; A Gruber; J H Griffin
Journal:  J Clin Invest       Date:  1997-06-01       Impact factor: 14.808

4.  Characterization of mini-protein S, a recombinant variant of protein S that lacks the sex hormone binding globulin-like domain.

Authors:  M Van Wijnen; J G Stam; G T Chang; J C Meijers; P H Reitsma; R M Bertina; B N Bouma
Journal:  Biochem J       Date:  1998-02-15       Impact factor: 3.857

5.  The effect of Arg306-->Ala and Arg506-->Gln substitutions in the inactivation of recombinant human factor Va by activated protein C and protein S.

Authors:  J O Egan; M Kalafatis; K G Mann
Journal:  Protein Sci       Date:  1997-09       Impact factor: 6.725

6.  Modeling zymogen protein C.

Authors:  L Perera; C Foley; T A Darden; D Stafford; T Mather; C T Esmon; L G Pedersen
Journal:  Biophys J       Date:  2000-12       Impact factor: 4.033

7.  Down regulation of prothrombinase by activated protein C during prothrombin activation.

Authors:  Paul Y Kim; Michael E Nesheim
Journal:  Thromb Haemost       Date:  2010-04-13       Impact factor: 5.249

8.  Interactions and inhibition of blood coagulation factor Va involving residues 311-325 of activated protein C.

Authors:  R M Mesters; M J Heeb; J H Griffin
Journal:  Protein Sci       Date:  1993-09       Impact factor: 6.725

9.  Prothrombinase complex assembly on the platelet surface is mediated through the 74,000-dalton component of factor Va.

Authors:  P B Tracy; K G Mann
Journal:  Proc Natl Acad Sci U S A       Date:  1983-04       Impact factor: 11.205

10.  Evidence of normal functional levels of activated protein C inhibitor in combined Factor V/VIII deficiency disease.

Authors:  W M Canfield; W Kisiel
Journal:  J Clin Invest       Date:  1982-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.